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Current treatment strategies for rheumatoid arthritis (RA)
consisting of disease-modifying anti-rheumatic drugs or
biological agents are not always effective, hence driving
the demand for new experimental therapeutics. The
antiproliferative capacity of proteasome inhibitors (PIs)
has received considerable attention given the success of
their first prototypical representative, bortezomib (BTZ),
in the treatment of B cell and plasma cell-related
hematological malignancies. Therapeutic application
of PIs in an autoimmune disease setting is much less
explored, despite a clear rationale of (immuno)
proteasome involvement in (auto)antigen presentation,
and PIs harboring the capacity to inhibit the activation
of nuclear factor-κB and suppress the release of
pro-inflammatory cytokines such as tumor necrosis
factor alpha and interleukin-6. Here, we review the
clinical positioning of (immuno) proteasomes in
autoimmune diseases, in particular RA, systemic lupus
erythematosus, Sjögren’s syndrome and sclerodema,
and elaborate on (pre)clinical data related to the impact
of BTZ and next generation PIs on immune effector cells
(T cells, B cells, dendritic cells, macrophages, osteoclasts)
implicated in their pathophysiology. Finally, factors
influencing long-term efficacy of PIs, their current
(pre)clinical status and future perspectives as anti-
inflammatory and anti-arthritic agents are discussed.(T/B cells, macrophages, synoviocytes), cytokines andIntroduction
Rheumatoid arthritis (RA) is a common autoimmune
disease characterized by synovial inflammation and hyper-
plasia, autoantibody production, and cartilage and bone de-
struction, the underlying cause of which lies in immune
regulatory factors such as the loss of tolerance [1]. How this
process is linked to a localized onset of inflammation in the* Correspondence: g.jansen@vumc.nl
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unless otherwise stated.joint is still unclear but it involves migration and accumula-
tion of immune effector cells, including macrophages and
osteoclasts, myeloid and plasmacytoid dendritic cells (DCs),
B cells and T cells [1]. Th17 subsets, which produce inter-
leukin (IL)-17 and IL-21, also play a crucial role in the de-
velopment of RA in combination with limited functional
capabilities of regulatory T cells (Tregs). Current therapies
for RA rely on early and aggressive treatment with disease-
modifying anti-rheumatic drugs (DMARDs), including
methotrexate and glucocorticoids and/or biological agents.
These mostly include antibodies to pro-inflammatory cy-
tokines, for example, tumor necrosis factor (TNF)α and
IL-6 and others, including rituximab (anti-CD20) and aba-
tacept (CTLA4 IgG1 fusion protein), which also interfere
with the underlying immune/inflammatory events. In gen-
eral, monotherapy with DMARDs has limited long-term
efficacy, probably as a consequence of multidrug resist-
ance. Large clinical studies with long-term follow-up
demonstrated that the use of combinations of conven-
tional DMARDs, particularly methotrexate, with biological
agents was highly effective in achieving clinical remission
and preventing radiological deterioration in approximately
50% of RA patients, but the remaining 50% of patients still
experienced insufficient disease activity reduction or
sustained active disease [2]. Therefore, in RA treatment
there is still room for investigational new drugs with novel
mechanisms of action, including antibody-guided and
small molecule-mediated targeting of specific cell types
their receptors, and intracellular (signaling) pathways
[1]. Janus kinase inhibitors and Spleen kinase inhibitors
represent examples of these latter drugs, displaying great
pre-clinical potential, but, as with biological agents, safety/
toxicity issues apply [3].
Proteasome inhibitors (PIs) may also fall in the category
of potentially attractive investigational drugs for their abil-
ity to (a) inhibit the activation of nuclear factor (NF)-κB
and transcriptional regulation of pro-inflammatory cyto-
kine release, and/or (b) induce apoptosis of activated
immune cells. The rationale of PIs to act as anti-tral. This is an Open Access article distributed under the terms of the Creative
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diseases, including RA, systemic lupus erythematosus
(SLE), Sjögren’s syndrome (SS) and scleroderma, has
been the subject of several recent publications and re-
views [4-6]. In this review, we cover the diversity and
relevance of constitutive and immunoproteasome sub-
types in immune competent cells involved in autoimmune
diseases, and provide an overview of several classes of re-
versible and irreversible PIs for therapeutic interventions.
Consistent with the chronic nature of the disease, it is also
of relevance to expand our knowledge on the efficacy of
PIs following long-term PI administration, and the pos-
sible acquisition of resistance to PIs. This review also elab-
orates on this issue.
Proteasome subtypes
The ubiquitin-proteasome system (UPS) plays a central
role in maintaining cellular homeostasis by controlling the
timely breakdown of many key proteins, including those
involved in cell cycle regulation, activation of transcription
factors (for example, NF-κB) and apoptosis induction
(Figure 1A,B). The proteasome has a 26S structure, which
consists of the 19S regulator and the 20S central proteo-
lytic core (Figure 2A). Three β-subunits within the 20S
core of the proteasome harbor its catalytic activity: the β5
subunit (PSMB5, chymotrypsin-like activity), the β1 sub-
unit (PSMB6, caspase-like activity) and the β2 subunit
(PSMB7, trypsin-like activity) [7]. Upon stimulation byFigure 1 Role of proteasomes in protein degradation and nuclear fac
their (functional) life-span, or damaged/misfolded proteins, are subject to d
by the proteasome initiates protein degradation to smaller peptides, which
for renewed protein synthesis or to trimmed peptides presented by major
blockade of nuclear factor (NF)-κB activation by the proteasome inhibitor b
natural inhibitor of NF-κB (that is, IκB) along with nuclear translocation of p
TNF, tumor necrosis factor.pro-inflammatory stimuli, for example interferon (IFN)-γ
or TNFα, these constitutive proteasome subunits can be
replaced by immunoproteasome subunits β5i (PSMB8,
LMP7), β1i (PSMB9, LMP2) and β2i (PSMB10, MECL1)
and to assemble immunoproteasomes, along with PA28
as regulatory cap (Figure 2B). Immunoproteasomes are
mainly found in cells of hematological origin in which they
convey specialized functions, including: a) facilitating en-
dogenous antigen presentation via major histocompatibility
complex (MHC) class I; b) splicing of antigenic peptides
and cross-presentation of exogenous antigens via MHC
class I on DCs; and c) preserving protein homeostasis after
IFN-γ-induced oxidative stress [5,8]. Beyond this, hybrid
variants of immunoproteasomes with constitutive subunits
also have been identified in murine heart tissue as well as
in human liver, colon, small intestine, kidneys, tumor
cells and DCs [9]. These hybrid forms displayed unique
antigen-processing properties, thereby expanding the rep-
ertoire of antigen presentation by specific cells. Apart from
constitutive proteasomes and immunoproteasomes, a third
proteasome variant, designated thymo-proteasomes, was
identified in cortical thymic epithelial cells. Their function
seems to be required for positive selection of CD8+ T cells
and in the control of cytokine release [10].
Proteasomes in inflammatory/autoimmune diseases
The prominent role of the UPS in multiple cellular pro-
cesses, including MHC-mediated antigen presentation,tor-κB activation. (A) After initial synthesis, proteins at the end of
egradation after conjugating with an ubiquitin (Ub) tag. Recognition
are further processed by aminopeptidases either to free amino acid
histocompatibility complex class I molecules. (B) Mechanism of
ortezomib. This inhibitory effect prevents the degradation of the
50/p65 and transcription of pro-inflammatory cytokines. IL, interleukin;
Figure 2 Subunit composition of constitutive and immunoproteasomes. (A) 20S core proteasome. (B) Fully assembled proteasome.
Coloured subunits represent catalytic subunits. IFN, interferon; TNF, tumor necrosis factor.
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it crucial in the development and progression of inflam-
matory and autoimmune diseases [5]. Given that cytokines
are regulatory factors in the formation of immunoprotea-
somes, it is conceivable that their increased levels would
coincide with chronic inflammation. Indeed, elevated
immunoproteasome levels have been associated with in-
flammation and the development and progression of auto-
immunity [11,12]. However, it is still a controversial issue
whether or not immunoproteasomes drive inflammatory
diseases or merely reflect the consequence of excessive
cytokine synthesis or cell stress. From knock-out mice ex-
periments, it was concluded that immunoproteasomes
have a protective function against the development of
autoimmunity [13]. This is supported by the finding that
triple knock-out mice for all three immunoproteasome
subunits displayed such a markedly altered repertoire of
antigenic peptides for MHC class I presentation that they
triggered an immune response to mice splenocytes [14].
Of note, mutations in PSMB8 (β5i) were implicated in ab-
errant immunoproteasome assembly and function causing
human disorders linked to an auto-inflammatory patho-
genesis [15]. As an alternative function, Seifert and col-
leagues [8] suggested that immunoproteasomes have an
increased intrinsic catalytic activity relative to constitutive
proteasomes and thereby prevent the accumulation of
degradation substrates that would otherwise aggregateduring inflammation. Studies by Nathan and colleagues
[16], however, reported that constitutive and immunopro-
teasomes bound and degraded ubiquitin conjugates at
similar rates and that immunoproteasomes did not protect
against experimental autoimmune encephalomyelitis, even
though immunoproteasome activity did increase the gen-
eration of peptides for MHC class I presentation.
Interestingly, circulating proteasomes were found in
serum samples of patients with autoimmune myositis,
SLE, primary SS, RA, and autoimmune hepatitis [17-19].
These circulating 20S proteasomes contained both consti-
tutive and immunoproteasome subunits and might serve
as potential biomarkers as each disease displayed different
proteasome patterns. Moreover, the increased levels of
circulating proteasomes in autoimmune diseases might
actually function as autoantigens that could induce an
autoimmune response. In fact, anti-proteasome auto-
antibodies were detected in sera of patients with RA,
SLE, myositis and multiple sclerosis [18,20,21]. These
antibodies interfere with the interaction between the
20S proteasome and P28 and thereby block proteasome
activation and functional capacity.
First and second generation proteasome inhibitors
The important role of the proteasome in the activation
of NF-κB has initiated research to develop PIs for thera-
peutic interventions for chronic inflammatory diseases
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[22] described the timeline of PI development starting
more than 40 years ago. Original studies on biochemical
mechanisms of protein degradation emerged with the de-
velopment of MG-132, a peptide aldehyde that blocked
proteasome function. About a decade ago, bortezomib
(BTZ), a boronic acid peptide, was the first PI that was ap-
proved for treatment of therapy-refractory multiple mye-
loma [23]. Development of BTZ as an anti-inflammatory
drug has taken a slower path, but preclinical evaluations
are still ongoing [22]. Recent reviews by Huber and Groll
[24], and Kisselev and colleagues [7] summarized chemical
and crystallography data of BTZ and second-generation
PIs designed to target and bind either reversibly or irre-
versibly to constitutive and/or immunoproteasomes. PIs
can be grouped into seven classes: aldehydes, vinyl sul-
fones, vinylamides (syrbactins), boronates, α’,β’-epoxyke-
tones, α-ketoaldehydes (glyoxals), and β-lactones [24].
Figure 3 and Table 1 provide an overview of the chemical
structure and other features (class, target, route of admin-
istration) of PIs that are currently under clinical develop-
ment. All of these PIs represent active site inhibitors,
interacting with the amino-terminal Thr1 site of the
proteasome catalytic subunits. Apart from these types
of PIs, non-competitive PIs have also been developed,
which bind to structural non-active subunits (for ex-
ample, proteasome subunit alpha type, α-subunits) or to
regulatory particles outside the proteasome catalyticFigure 3 Chemical structures of proteasome inhibitors. Asterisks indica
anti-inflammatory properties.core [25]. Hereafter, we further elaborate on active-site PIs
under pre-clinical evaluation as anti-inflammatory agents.
Effects of inhibition of the proteasome system on
immune effector cells
Pre-clinical and clinical studies have demonstrated that
BTZ elicits immunosuppressive effects either by interfer-
ing in the NF-κB signaling pathway or by inducing im-
paired development or depletion of specific blood cell
types [26-29]. It is well recognized that particularly (ma-
lignant) plasma cells as professional antibody secreting
cells are extremely sensitive to PIs. Mechanistically, prote-
asome inhibition leads to aberrant degradation of defective
ribosomal products in the endoplasmatic reticulum. The
overwhelming endoplasmatic reticulum stress provoked
by PIs coincides with PI-induced inhibition of NF-κB acti-
vation, dampening an anti-apoptotic response. Together,
these dual effects lead to the terminal unfolded protein re-
sponse and apoptotic cell death in myeloma cells as well
as in normal plasma cells [30-32]. Table 2 summarizes the
impact of BTZ (first generation) and next-generation PIs
on various types of immune effector cells (T cells, B cells,
DCs, monocytes, macrophages, osteoclasts), which is dis-
cussed in greater detail below.
Monocytes, macrophages and osteoclasts
Macrophage precursors are released into the circulation
as monocytes, from where they migrate into tissues.te that the compound has not been evaluated for potential
Table 1 Properties of proteasome inhibitors and clinical administration route
Proteasome inhibitor Class Target(s) Administration route
MG-132 Aldehyde CP and IP Not known
Bortezomib Boronate CP and IP Intravenous/subcutaneous
Carfilzomib (PR-171) α’,β’-Epoxyketone CP and IP Intravenous
Delanzomib (CEP-18770/cephalon) Boronate CP and IP Oral
ONX 0912 (PR-047/oprozomib) α’,β’-Epoxyketone CP and IP Oral
ONX 0914 (PR-957) α’,β’-Epoxyketone IP Intravenous
MLN9708* (ioxazomib): hydrolizes to MLN2238 Boronate CP and IP Oral
Marizomib* (NPI-0052/salinosporamide A) β-Lactone CP and IP Intravenous and oral
PR-924* (IPSI) α’,β’-Epoxyketone IP Intravenous
CP targeting refers primarily to PSMB5 (β5) subunit; IP targeting refers primarily to PSMB8 (β5i) subunit. Asterisks indicate that the compound has not been
evaluated for potential anti-inflammatory properties. CP, constitutive proteasome; IP, immunoproteasome; IPSI, immunoproteasome-specific inhibitor.
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are divided into subpopulations harboring both protective
and pathogenic functions. Pro-inflammatory cytokines, for
example, TNFα, IL-18, IL-12 and IL-23, released from
M1-like macrophages have been identified as important
mediators in several autoimmune diseases. Consequently,
options for therapeutic interventions, including for RA,
might include non-specific and specific targeting of M1Table 2 Overview of effects of proteasome inhibitors on imm
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conjunction with inhibition of the pro-inflammatory me-
diators TNF-α and IL-8, while increasing the release of
the anti-inflammatory mediator IL-10. More selective in-
hibition of the immunoproteasome subunit PSMB8 (β5i)
by the immunoproteasome inhibitor ONX 0914 (formerly
designated PR957) attenuated progression of experimental
arthritis by blocking production of IL-23 by activated
monocytes [27].
Osteoclasts represent specialized bone-resident macro-
phages involved in bone remodeling through bone resorp-
tion. This process is often affected in chronic inflammatory
diseases, leading to accelerated bone loss triggered by the
receptor activator of nuclear factor-κB. This receptor, be-
longing to the TNF superfamily, is expressed on osteoclasts
and is a critical stimulator of the differentiation and func-
tional activity of these cells and thus of promotion of bone
resorption [1].
The impact of BTZ on human osteoclastogenesis is
not fully resolved, with one study reporting beneficial ef-
fects on bone resorption [34], and another noting aggrava-
tion of bone resorption by BTZ treatment [35]. Whether
or not these differential effects are explained by utilization
of different experimental models (TNFα-induced versus
adjuvant-induced) merits further exploration. It cannot be
excluded that effects of BTZ on bone are indirect as oste-
oclastogenesis is upregulated in active disease; suppression
of the inflammatory process by PI treatment would then
counteract the elevated bone resorption.
T cells
Crucial for the function of T lymphocytes are T-cell re-
ceptor engagement, co-stimulation and distinct cytokine
receptor ligation, which promote their activation and/or
differentiation into specialized subsets. Mounting evidence
indicates that the inappropriate regulation of Th17 sub-
sets, which produce IL-17 and IL-21, plays a crucial role
in the development of a wide range of autoimmune disor-
ders, including RA and SLE [36]. Th17 cells are develop-
mentally closely related to Tregs, whose defective function
has been put forward as a cause of tolerance failure in sev-
eral human autoimmune diseases, including RA, psoriasis
and granulomatosis with polyangiitis. Indeed, conversion
of immunosuppressive Tregs to pro-inflammatory Th17
cells under the influence of IL-6, IL-23 and transforming
growth factor-β, may play an important role in the gener-
ation and/or aggravation of autoimmunity [1].
The importance of proteasome catalytic activity in the
activation of T cells has been underscored as PIs have been
extensively explored for their possible immunosuppressive
properties in the treatment of deregulated and unwanted
T-cell-mediated immune responses, including those that
contribute to the pathogenesis of autoimmune diseases.
Direct effects of constitutive and immunoproteasomeinhibition by BTZ, epoxomycin and lactacystin on T cells
include induction of apoptosis in activated and proliferat-
ing cells as well as suppression of activation, proliferation,
survival and important immune functions of Th cells [28].
Additionally, Van der Heijden and colleagues [37] showed
that BTZ inhibited the release of NF-κB-inducible cyto-
kines by activated T cells from RA patients. Other studies
indicated that PSMB8 (β5i) inhibition in T cells can serve
as a mechanistic basis for the attenuation of autoimmune
diseases. Specifically, Muchamuel and colleagues [27]
showed that selective inhibition of the immunoprotea-
some by ONX 0914 (PR-957) blocked production of
IFN-γ and IL-2 by T cells in mouse models of arthritis,
thereby reversing disease symptoms along with reducing
cellular infiltration in arthritic lesions and autoantibody
levels. Further investigations into the role of immuno-
proteasomes in mouse T cells showed that immunopro-
teasome deficiency or blocking of PSMB8 (β5i) function
impaired Th1 differentiation without affecting Th2 dif-
ferentiation. Moreover, the equilibrium between Th17
and Tregs shifted toward the latter, most likely by inhi-
biting the phosphorylation of STAT3 [38]. Altogether,
both direct and indirect effects of PIs on suppression of
T cell activation seem beneficial from an RA therapeutic
perspective [1].
Dendritic cells
DCs are the most powerful professional antigen-presenting
cells and also control other players and processes of the
immune system through the release of regulatory or stimu-
latory cytokines, depending on their developmental stage
and activation state. DCs, for instance, control peripheral
tolerance by inducing either anergy or depletion of auto-
reactive T cells. Two major DC subsets are derived from a
common hematopoietic progenitor cell and abnormalities
in both myeloid DCs as plasmacytoid DCs are associated
with the development, maintenance and progression of
several autoimmune diseases [39]. For their development
and function, DCs heavily rely on the UPS and thus the ef-
fects of proteasome inhibition on the functionality of DCs
have been the subject of extensive studies. In myeloid DCs,
proteasome inhibition by BTZ reduced the expression of
the DC-specific subset and activation markers (CD40,
CD86, CD80, HLA-DR, CD206, CD209 and CD83) and
induced apoptosis (upregulation of the pro-apoptotic pro-
tein Bax), inhibition of Toll-like receptor signaling, and
suppression of cytokine release (IL-12, TNFα) due to im-
paired nuclear translocation of the NF-κB subunits RelA
and RelB. Proteasome-inhibited DCs also failed to prime
allogeneic T cells [6,29]. This susceptibility depended on
the DC maturation stage as immature DCs appeared to be
much more prone to respond to BTZ than mature DCs
[40]. In other pre-clinical models of plasmacytoid DCs,
effects of proteasome inhibition with BTZ, and also
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of Toll-like receptor trafficking, IFN-α and IL-6 produc-
tion and induction of apoptosis [41,42]. DC development
and function upon differentiation in the presence of IFN-
α were as equally sensitive to inhibition by BTZ as by the
immunoproteasome inhibitor ONX 0914 (Verbrugge and
colleagues, submitted).
Importantly, all these preclinical evaluations of PI-
induced effects on human DCs span a relatively short
drug exposure time and involve models of inflammatory
DC differentiation, whereas clinical efficacy in chronic
inflammation is often manifested after multiple cycles of
drug administration and will also impact steady-state
DC development [23]. Examining the impact of long-
term BTZ exposure in CD34+ DC progenitors in a sus-
tainable cell line model of steady-state Langerhans cell
differentiation revealed early differentiation in precursor
cells along with enhanced cytokine-driven Langerhans
cell differentiation and maturation. Mechanistically, this
effect was associated with enhanced NF-κB subunit RelB
activation (Verbrugge and colleagues, submitted). Blanco
and colleagues [39] reviewed their cytokine-induced
monocyte-to-DC activation model that was created to
demonstrate the contribution of inflammatory DCs aris-
ing under the influence of TNFα and type I IFNs (IFN-α
and -β) to the development of autoimmunity. In par-
ticular, a pathogenic excess of IFNα/β in SLE, SS, derm-
atomyositis and early stages of psoriasis, along with an
excess of TNFα in RA, inflammatory bowel disease,
Crohn’s disease and psoriasis, may induce the generation
of detrimental monocyte-derived inflammatory DCs. Tar-
geting the production of both TNFα by myeloid DCs and
type I IFNs by plasmacytoid DCs in these diseases might
therefore be an attractive strategy to dampen chronic in-
flammation while maintaining protective immunity. This
concept proved valid in an IFNα-driven monocyte-to-DC
differentiation model exposed to BTZ and ONX 0914
(Verbrugge and colleagues, submitted).
B lymphocytes
Depending on their developmental phase, B cells are in-
volved in antigen presentation to T cells, the regulation
of immune responses through cytokine production or
the production of antibodies. Over the past decade, B-
cell-depleting agents such as the CD20-targeted antibody
rituximab have highlighted the essential role B cells play
in the pathogenesis of various autoimmune diseases, in-
cluding RA and SLE [43]. The UPS is critically involved
in B-cell development and function, for example through
its regulation of CD20 expression, the expression of the
B-cell receptor and B-cell antigen presentation [44]. Van
Anken and colleagues [45] reported a series of changes
occurring during differentiation of B cells into plasma
cells, starting with the expansion of metabolic capacityand the secretory machinery to accommodate the massive
IgM production by plasma cells. Initially, it was rational-
ized that the increased protein turn-over in these cells
would be accompanied by increased proteasome activity
and that this feature would render them particularly sus-
ceptible to proteasome inhibition and accumulation of
polyubiquitinated proteins, eliciting an apoptotic response.
Later studies indicated that this increased susceptibility to
proteasome inhibition was not necessarily due to increased
proteasome levels and activity, but rather to stabilization of
pro-apoptotic proteins leading to cell death [46]. Notably,
several rodent models exhibited this increased susceptibil-
ity of plasma cells to proteasome inhibition. Neubert and
colleagues [26] showed that reduced nephritis in mice with
lupus-like disease was attributed to BTZ-induced plasma
cell reduction. Beneficial effects from BTZ therapy were
observed also in an experimental model of myasthenia
gravis [47]. Also, selective inhibition of the immunoprotea-
some by ONX 0914 suppressed progression of experimen-
tal arthritis accompanied by a decrease in circulating levels
of autoantibodies [27]. The next-generation PIs delanzo-
mib and CFZ also showed promising anti-inflammatory
effects by reducing autoantibody levels in mice with lupus
[42]. These preclinical findings hold promise for the treat-
ment not only of autoimmune diseases with increased
plasma cell levels, but also for those in which autoantibody
levels are critical determinants. Lastly, in vitro studies with
human B lymphoblastoid cells showed that chronic expos-
ure to BTZ led to upregulated CD20 expression levels due
to impaired proteasome-mediated CD20 degradation. This
feature may set a rationale for combination treatment of
PIs with anti-CD20/rituximab [48].
Mechanisms of proteasome inhibitor resistance
and implications for autoimmunity
Regardless whether it concerns classical DMARDs, bio-
logical agents or experimental drugs, loss of efficacy due to
primary or acquired resistance remains a recurrent theme
in sustaining long-term therapeutic effects during treat-
ment of autoimmune diseases [49,50]. For the PI BTZ,
emergence of acquired resistance has been associated with
reduced efficacy in the treatment of hematological malig-
nancies [23]. In an autoimmune disease setting, where pa-
tients often require chronic drug administration, long-term
efficacy may also be potentially hampered by the emer-
gence of resistance phenomena. Over the past years,
studies based on in vitro model systems revealed several
mechanisms that may contribute to diminished efficacy
with PIs and acquisition of resistance. One mechanism of
PI resistance relates to the increased expression of pro-
teasome subunits as a primary response to overcome PI
targeting. In this respect, PSMB5 (β5) subunits were
often found upregulated upon BTZ exposure in BTZ-
resistant cells to compensate for inhibitory effects on
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and colleagues [52] observed that intrinsic factors and ab-
errant proteasome activation established dysregulation of
β1i proteasome subunit expression in B lymphocytes of SS
patients, conferring diminished PI inhibition and resist-
ance to apoptosis. PI exposure and resistance may also
provoke alterations in the relative composition of consti-
tutive and immunoproteasome subunits, the impact of
which on immune functions is not clear [53,54]. Another
mechanism of acquired resistance to PIs is mediated by
point mutations in the PSMB5 gene encoding the PSMB5
(β5) subunit. This introduces amino acid alterations in the
BTZ binding pocket of the PSMB5 (β5) subunit of the
proteasome and confers diminished efficiency of BTZ
binding. These mutations have been described in BTZ-
resistant hematological cell line models, but have not yet
been reported in biopsies or cell samples from patients ex-
periencing clinical resistance to BTZ [51,53,55]. Interest-
ingly, nature provides a precedent for PSMB5 mutations
as the marine bacterium Salinospora tropica generates
self-resistance to the PI salinosporamide A (marizomib) it
produces by upregulating a mutated form of the PSMB5
(β5) subunit that harbors a single amino acid substitution
identical to those found in hematological cell lines with
acquired BTZ resistance [51,53]. A third recognized resist-
ance mechanism operates via selective drug efflux trans-
porters of the ATP-binding cassette family, known to
confer multidrug resistance, which could facilitate cellular
extrusion of specific PIs [56]. Whereas BTZ appeared to
be a relatively poor substrate for drug efflux transporters,
next-generation PIs such as CFZ, ONX 0912 (oprozomib)
and ONX 0914 were found to be proficient substrates for
the efflux transporter MDR1 (P-glycoprotein (Pgp)). Of
interest, inhibition of Pgp could reverse resistance to these
[51,54]. Since Pgp is constitutively expressed on lympho-
cytes from RA patients, and its expression is correlated
with disease activity, both basal levels of expression and
upregulated levels upon long-term administration could
be limiting factors in sustaining long-term efficacy [56].
Primary resistance to BTZ has been associated with
upregulated expression of heat shock proteins [57]. This
could be of relevance for PI treatment of autoimmune
diseases since enhanced expression of heat shock proteins
has been described in various inflammatory conditions,
such as RA, type 1 diabetes, and atherosclerosis. Finally,
impaired inhibition of NF-κB and activation of PI3K/Akt
pro-survival pathways through increased secretion of the
insulin-like growth factor (IGF)-1 and enhanced activation
of the IGF-1 receptor may also contribute to BTZ resist-
ance [58]. This latter notion could have implications for
the treatment of autoimmune diseases since IGF-1 is pro-
duced by plasma cells, in the bone marrow microenviron-
ment, and under various disease conditions. Together, the
expanded knowledge of molecular mechanisms that couldimpact (pre)clinical activity of various PI subclasses may
be exploited for rational clinical application and to sup-
port optimal efficacy.
Current clinical status of proteasome inhibitors in
autoimmune disease
Other than for malignant diseases and in the setting of
graft-versus-host disease, clinical application of BTZ or
next-generation PIs in the treatment of autoimmune dis-
eases is still at an early stage. Moran and colleagues [6]
discussed a few case reports describing clinical experi-
ence with BTZ in immune-mediated diseases. These in-
clude reports of patients with autoimmune diseases such
as SLE and refractory autoimmune hemolytic anemia
(chronic cold agglutinin disease) where beneficial effects
of BTZ were accompanied by improved laboratory
findings consisting of reduced anti-extractable nuclear
antigen levels, reduced anti-double-stranded DNA anti-
body levels, and normalization of complement levels and
platelet count. These studies were further corroborated by
Hiepe and colleagues [59], who reported that refractory
SLE patients responded to BTZ therapy. Currently, there
are only three registered clinical trials for BTZ in auto-
immune diseases and these include refractory cold agglu-
tinin disease, IgA nephropathy and proliferative lupus
nephritis, the last of which has been withdrawn prior to
initiation [60]. Registered clinical trials for autoimmune
diseases with next-generation PIs (for example, CFZ,
oprozomib, delanzomib or ONX 0914) are still lacking.
Obviously, successful implementation of PI therapies
in autoimmune diseases will be dependent on managing
toxic side effects. In early clinical studies of BTZ
treatment of multiple myeloma, peripheral neuropathy
emerged as one undesirable side effect, though others
were also documented - for example, pancytopenia,
congestive heart failure, pulmonary edema, gastrointes-
tinal hemorrhage, disseminated herpes zoster, sepsis
and renal failure [23]. Peripheral neuropathy appeared
to be related to non-proteasomal inhibition by BTZ of
HtrA2/Omi, a neuronal survival protease [61]. Currently,
modified schedules and routes of administration (subcuta-
neous versus intravenous) and (orally) available second
generation PIs have improved their efficacy, safety and
toxicity profiles [23].
Future perspectives/conclusion
There is still a long way to go before the transition of
PIs from experimental to standard therapeutics. For this
to occur in RA treatment PIs would have to be better
than the powerful and relatively safe anti-rheumatic drugs
that are already on the market or they should work better
in combination with conventional DMARDs and/or bio-
logics. However, for autoimmune diseases other than RA
for which therapeutic options are more limited - for
Verbrugge et al. Arthritis Research & Therapy  (2015) 17:17 Page 9 of 10example, SLE, SS and scleroderma - PIs deserve further
consideration.
In conclusion, preclinical evaluation of BTZ and next-
generation PIs for the treatment of autoimmune diseases
such as RA is generally promising. PIs have the capacity
not only to induce cell-specific apoptosis (for example,
of autoantibody-producing plasma cells), but also to target
pro-inflammatory cytokines and their receptors and dis-
rupt intracellular signaling pathways in pro-inflammatory
immune effector cells.
Lessons learned from preclinical and clinical observa-
tions with BTZ in hematological malignancies indicated
that the timing and scheduling of drug administration is
a key factor in optimized treatment and to minimize BTZ-
related toxicity, side effects from which include peripheral
neuropathy, thrombocytopenia, diarrhea and an increased
risk of developing infectious complications [6,23]. These
observations represent clinically relevant factors to con-
sider in the treatment of autoimmune/inflammatory
disorders, in particular when drug administration would
be more chronic. The risk of thrombocytopenia and poly-
neuropathy might be more acceptable in patients with
malignant diseases than in those suffering from chronic
autoimmune diseases. Notably, reduction of side effects
accompanied by similar levels of efficacy were observed
upon subcutaneous BTZ administration [23]. Beyond this,
the next generation PI CFZ and the orally delivered next-
generation PIs MLN9708 or ONX 0912 (oprozomib)
might also overcome these toxicities.
Experience from PI treatment of hematological malig-
nancies will expand insights into mechanisms related to
toxicity or the development of resistance. Meanwhile, the
role of the immunoproteasome and the possible advan-
tages of its specific targeting merit further investigation
and might prove to be key in the reduction of chronic in-
flammation with acceptable unwanted side effects.
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